Skip to main content
OpenTrials
Completed

NCT Number: NCT01845935

Cryoablation of Venous Vascular Malformations

To now, two alternatives for the management of venous vascular malformations are recognized, appropriate to the location, size and patients: sclerosis and surgery. However, sclerosis is effective on symptoms in 80% of cases and excision removes the malformation completely or partially, but it is aggressive and recurrences are common.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

University Hospital Bordeaux, France

Bordeaux, 33076, France

About this study

In order to propose an additional alternative option, cryoablation has been recently tested with promising results. Therefore, the purpose of this study is to evaluate the safety and efficacy of cryotherapy on venous vascular malformations.

Fourteen patients will be included after discussion in multidisciplinary meeting. Patients will be follow until 6 months to evaluate the safety and the 6 months efficacy on symptoms. A MRI will be perform at 6 months to evaluate the size of ablated zone following RECIST criteria.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 18 years,
  • Initial radiological diagnosis of venous or glomovenous vascular malformation proved by Doppler ultrasound and MRI,
  • Recurrence of symptoms after initial treatment,
  • Symptomatic deformation :pain, tangible mass,functional discomfort
  • Recurrence after treatment by surgery or sclerosis
  • Cryotherapy considered technically feasible after discussion in multidisciplinary committee,
  • Localization at distance from the skin and major neurovascular structures,
  • Absence of contra-indication of anaesthesia,
  • Signed informed consent,
  • Coverage by French social security

Exclusion criteria

  • Localization of the lesion does not allow the implementation of cryotherapy in adequate conditions: ablation zone too close to the major anatomic structures (nerve),
  • TP <50% TCA> 1.5 x control, anticoagulation
  • Platelets <90000/mm3,
  • Progressive infection
  • Patient included in another clinical study,
  • Unable to undergo medical tests for geographical, social or psychological,
  • Adult under a legal guardianship or unable to consent,
  • Pregnancy and breastfeeding.

Treatment and study plan

Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)

Device

Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.

Primary outcomes

  1. To evaluate the safety of cryoablation by measuring the immediate complications using NCI-CTCAE toxicity scale.

    Time frame: 7 days after cryoablation

  2. To evaluate the safety of cryoablation by measuring the delayed complications using NCI-CTCAE toxicity scale.

    Time frame: 1 month after cryoablation

  3. To evaluate the safety of cryoablation by measuring the delayed complications using NCI-CTCAE toxicity scale.

    Time frame: 2 months after cryoablation

  4. To evaluate the safety of cryoablation by measuring the late complications using NCI-CTCAE toxicity scale.

    Time frame: 6 months after cryoablation

Secondary outcomes

  1. All adverse events using NCI-CTCAE

    Time frame: 7 days, 1 month ,2 months + 6 months after cryoablation

  2. Clinical response (decrease of pain and/or functional discomfort)

    Time frame: 6 months after cryoablation

  3. Imaging response (RECIST 1.1)

    Time frame: 6 months after cryoablation

  4. Quality of life using QLQ-C30

    Time frame: 2 months & 6 months after cryoablation

  5. Pain using visual analogue scale

    Time frame: 7 days, 1 month ,2 months & 6 months after cryoablation

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Cryoablation of Venous Vascular Malformations Located in Soft Tissues

Acronym: CRYOMAV

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
May 3, 2013
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.